Gemphire Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease. Co.'s product candidate, gemcabene, has been tested as monotherapy and in combination with statins and other drugs. Within dyslipidemia, indications include Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, Severe Hypertriglyceridemia and Nonalcoholic Steatohepatitis. We show 14 historical shares outstanding datapoints in our GEMP shares outstanding history coverage, used to compute GEMP market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing GEMP market cap history over the course of time is important for investors
interested in comparing GEMP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of GEMP versus a peer is one thing; comparing
GEMP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like GEMP can fluctuate over the course of history.
With this page we aim to empower investors researching GEMP by allowing them to research the GEMP market cap history. |
Free GEMP Email Alerts:
Video: The Importance of Market Cap
